BCRX BioCryst Corp: Forward P/S Multiple
Staff dynamics and the hiring of sales experts are driving the development vector for BioCryst (BCRX), while the projected P/S ratio reflects the current market trend. BioCryst develops oral molecules for rare pathologies using protein crystallography. The implementation of green chemistry principles reduces production toxicity. The 2.00 metric is recorded as the baseline value, concluding the business valuation analysis relative to expected revenue.
Summary analytical data breakdowns for BioCryst Corp (BCRX)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- business debt structure and liquidity details:
- financial results and valuation multiples details:
BCRX - Profit After Payment of Taxes|Projected Future Earnings BioCryst|BCRX - Price to Earnings Ratio|Forward P/E Multiple BioCryst Pharmaceuticals Inc|BCRX - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioCryst Corp|BCRX - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months BioCryst|BCRX - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months biocryst.com|BCRX - Earnings per share trend in current year|Earnings growth forecast for next year BioCryst
- sales volume and revenue indicators:
Summary company analysis:BioCryst Pharmaceuticals (BCRX)
Forward P/S measures a company's market value relative to its expected revenue for the coming year, determining the extent of the premium paid for future cash flows. This ratio allows an investor to identify the boundaries of a fair valuation and the risks of a correction in the event of excessive market optimism. The current value of 2.00 for the forward P/S of BioCryst (BCRX) reflects market expectations for the capitalization of BioCryst. Stable demand for the patented drug for angioedema therapy justifies the current multiplier level, turning revenue into a predictable asset.
Competitor analysis
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA: Price-to-Projected Revenue Ratio|PTGX: Forward P/S Multiple|IMVT - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Kiniksa|Market Cap to Future Revenue Ratio Grifols SA GRFS|Forward P/S Multiple ADPT|Forward Price-to-Revenue Multiple Celldex Corp CLDX|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|Forward Price to Sales VERA|DNTH: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Pharvaris NV|AbCellera Biologics Inc (ABCL) - Price-to-Projected Revenue Ratio|TRML - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PGEN|PHAR (pharming.com) - Price to Expected Revenue Ratio|Forward P/S Multiple NKTR|Price-to-Projected Revenue Ratio UPB (Upstream Bio, Inc.)|Forward P/S Multiple ZBIO (Zenas Biopharma, Inc.)|IMNM - Forward Price-to-Revenue Multiple|GOSS - Price-to-Projected Revenue Ratio|Forward Price to Sales KALV (kalvista.com)|SEPN (Septerna) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue PVLA|Price-to-Projected Revenue Ratio Savara Corp|Rigel Corp - Future Price to Revenue|Forward P/S Multiple ANAB|ATXS (astriatx.com) - Forward Price to Sales|Forward P/S Multiple ENGN (enGene)|Forward P/S Multiple RAPT Therapeutics Inc. RAPT|JBIO - Price-to-Projected Revenue Ratio|Forward Price to Sales ACRS (Aclaris Therapeutics, Inc)|Kyverna Therapeutics (KYTX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple tizianalifesciences.com|CABA (Cabaletta Bio) - Forward P/S Multiple|Forward P/S Multiple Ventyx Biosciences Inc.|Forward Price-to-Revenue Multiple THTX (Theratechnologies Inc)|AVTX (Avalo Therapeutics Inc) - Forward Price to Sales|Forward P/S Multiple ELDN (Eledon Pharmaceuticals)|Market Cap to Expected Sales Ratio agenusbio.com (AGEN)|CLYM - Price-to-Projected Revenue Ratio|Zura Bio Ltd (ZURA) - Forward Price-to-Revenue Multiple|aTyr (ATYR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Adagene Inc.|Forward Price-to-Revenue Multiple IMA|Forward P/S Multiple Shattuck Therapeutics|Price-to-Projected Revenue Ratio Equillium, Inc. (EQ)|connectbiopharm.com - Market Cap to Projected Revenue|Forward P/S Multiple IMUX (Immunic)|Atara Biotherapeutics, Inc. (ATRA) - Market Cap to Future Revenue Ratio|InflaRx GmbH - Forward P/S Multiple|XFOR: Price-to-Projected Revenue Ratio|ACET: Forward P/S Multiple|CELU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio INmune Bio Corp|Market Cap to Future Revenue Ratio Barinthus Biotherapeutics Corp BRNS|Forward P/S Multiple KZR|Forward Price-to-Revenue Multiple sabbiotherapeutics.com SABS|Price-to-Projected Revenue Ratio Akari Therapeutics Plc AKTX|Forward Price to Sales ENLV|QTTB: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio GeoVax Corp|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|IBIO - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CARM|XTLB (XTL Biopharmaceuticals Ltd) - Price to Expected Revenue Ratio|Forward P/S Multiple BOLT|Price-to-Projected Revenue Ratio HCWB (hcwbiologics.com)|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM - Forward Price-to-Revenue Multiple|ADTX - Price-to-Projected Revenue Ratio|Forward Price to Sales GRI (GRI Bio Inc)|XRTX (XORTX) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue HIND|Price-to-Projected Revenue Ratio Revelation Biosciences|indaptusrx.com - Future Price to Revenue|Forward P/S Multiple SCNI|CALI (calcimedica.com) - Forward Price to Sales|Forward P/S Multiple AFMD (Affimed N.V.)|Forward P/S Multiple Allakos Inc ALLK|HOOK - Price-to-Projected Revenue Ratio|Forward Price to Sales IGMS (IGM Biosciences, Inc.)|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Ocean Biomedical Inc|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Forward P/S Multiple Third Harmonic Bio Inc
